Clinical Trial Update: A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy [Phase 1]

View source ↗

Summary

Phase 1 results are reported for C-CAR066 in patients with relapsed/refractory diffuse large B-cell lymphoma who previously received CD19 CAR-T therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• C-CAR066

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Diffuse Large B Cell Lymphoma | Phase 1 | Status: COMPLETED